Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ENTA Stock Forecast 2025-2026
$7.50
Current Price
$160.32M
Market Cap
Buy 3
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to ENTA Price Targets
+220.0%
To High Target of $24.00
+166.7%
To Median Target of $20.00
-33.3%
To Low Target of $5.00
ENTA Price Momentum
0.0%
1 Week Change
+30.4%
1 Month Change
-41.6%
1 Year Change
+30.4%
Year-to-Date Change
-56.5%
From 52W High of $17.24
+83.4%
From 52W Low of $4.09
📊 TOP ANALYST CALLS
Did ENTA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Enanta is one of their latest high-conviction picks.
Latest ENTA Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ENTA has a bullish consensus with a median price target of $20.00 (ranging from $5.00 to $24.00). The overall analyst rating is Buy (7.6/10). Currently trading at $7.50, the median forecast implies a 166.7% upside. This outlook is supported by 3 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Roy Buchanan at JMP Securities, projecting a 220.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENTA Analyst Ratings
3
Buy
1
Hold
1
Sell
ENTA Price Target Range
Low
$5.00
Average
$20.00
High
$24.00
Current: $7.50
Latest ENTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $24.00 |
| Feb 11, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $21.00 |
| Feb 11, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $18.00 |
| Dec 24, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $18.00 |
| Nov 26, 2024 | Baird | Brian Skorney | Outperform | Maintains | $20.00 |
| Nov 26, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $21.00 |
| Oct 10, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $27.00 |
| Oct 9, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $22.00 |
| Sep 27, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $22.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $27.00 |
| Aug 6, 2024 | JP Morgan | Eric Joseph | Underweight | Maintains | $10.00 |
| May 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $27.00 |
| May 7, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $22.00 |
| Feb 8, 2024 | JP Morgan | Eric Joseph | Underweight | Maintains | $11.00 |
| Nov 22, 2023 | Oppenheimer | Jay Olson | Perform | Maintains | $21.00 |
| Nov 21, 2023 | JMP Securities | Roy Buchanan | Outperform | Maintains | $23.00 |
| Nov 21, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $28.00 |
| Oct 23, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $30.00 |
| Oct 2, 2023 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $15.00 |
| Sep 19, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $48.00 |
Enanta Pharmaceuticals Inc. (ENTA) Competitors
The following stocks are similar to Enanta based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enanta Pharmaceuticals Inc. (ENTA) Financial Data
Enanta Pharmaceuticals Inc. has a market capitalization of $160.32M with a P/E ratio of -1.4x. The company generates $64.46M in trailing twelve-month revenue with a -149.6% profit margin.
Revenue growth is -12.5% quarter-over-quarter, while maintaining an operating margin of -164.3% and return on equity of -74.3%.
Valuation Metrics
Market Cap
$160.32M
Enterprise Value
$181.17M
P/E Ratio
-1.4x
PEG Ratio
-1.6x
Price/Sales
2.5x
Growth & Margins
Revenue Growth (YoY)
-12.5%
Gross Margin
N/A
Operating Margin
-164.3%
Net Margin
-149.6%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+120.6%
Current Ratio
5.3x
Debt/Equity
231.1x
ROE
-74.3%
ROA
-17.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Enanta Pharmaceuticals Inc. (ENTA) Business Model
About Enanta Pharmaceuticals Inc.
What They Do
Biotechnology company focused on drug development.
Business Model
The company generates revenue through the discovery and development of small molecule drugs, particularly for viral infections and liver diseases. Enanta collaborates with major pharmaceutical companies for commercialization, particularly in the hepatitis C treatment space, which bolsters its financial performance.
Additional Information
Enanta has a strong pipeline targeting critical health issues like HCV, RSV, and NASH, highlighting its role in advancing medical breakthroughs. Based in Watertown, Massachusetts, it operates in a competitive biotech sector, leveraging expertise in medicinal chemistry and drug development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
131
CEO
Dr. Jay R. Luly Ph.D.
Country
United States
IPO Year
2013
Website
www.enanta.comEnanta Pharmaceuticals Inc. (ENTA) Latest News & Analysis
Latest News
Quick Summary
Enanta Pharmaceuticals announced FDA approval for an expanded label of MAVYRET® as the only eight-week treatment for adults and pediatric patients aged three, enhancing its market position.
Why It Matters
FDA approval for MAVYRET® expands its market potential, potentially increasing sales and driving Enanta Pharmaceuticals' stock value higher. Positive regulatory news boosts investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) CEO Jay R. Luly will speak at the Jefferies Global Healthcare Conference on June 5, 2025. A live webcast will be available for the event.
Why It Matters
Enanta Pharmaceuticals’ participation in a prominent healthcare conference may boost visibility, attract investors, and signal potential advancements in their drug development pipeline.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) will present Phase 2 study data on zelicapavir for RSV in young children as an E-Poster at the ESPID 2025 meeting on May 2.
Why It Matters
The upcoming data presentation on zelicapavir's Phase 2 study may indicate the drug's potential efficacy, influencing Enanta Pharmaceuticals' market valuation and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
1 month ago
Quick Summary
Enanta Pharmaceuticals (ENTA) has a consensus price target suggesting a 189.6% upside. Positive earnings estimate revisions may indicate potential near-term stock growth.
Why It Matters
A 189.6% price target suggests significant growth potential for Enanta Pharmaceuticals, and positive earnings revisions indicate possible near-term stock appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
1 month ago
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) reported Q2 fiscal results, highlighting the enrollment of 180 patients in their RSVHR study, as they advance their virology and immunology pipeline.
Why It Matters
Enanta's successful patient enrollment in its RSVHR trial signals progress in its drug pipeline, potentially increasing its value and attracting investor interest in future developments.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (ENTA) reported a quarterly loss of $1.06 per share, slightly worse than the expected loss of $1.04, but an improvement from a loss of $1.47 per share a year prior.
Why It Matters
Enanta's larger-than-expected loss could signal ongoing financial struggles, impacting investor sentiment and stock performance, despite year-over-year improvement.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About ENTA Stock
What is Enanta Pharmaceuticals Inc.'s (ENTA) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Enanta Pharmaceuticals Inc. (ENTA) has a median price target of $20.00. The highest price target is $24.00 and the lowest is $5.00.
Is ENTA stock a good investment in 2025?
According to current analyst ratings, ENTA has 3 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $7.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENTA stock?
Wall Street analysts predict ENTA stock could reach $20.00 in the next 12 months. This represents a 166.7% increase from the current price of $7.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enanta Pharmaceuticals Inc.'s business model?
The company generates revenue through the discovery and development of small molecule drugs, particularly for viral infections and liver diseases. Enanta collaborates with major pharmaceutical companies for commercialization, particularly in the hepatitis C treatment space, which bolsters its financial performance.
What is the highest forecasted price for ENTA Enanta Pharmaceuticals Inc.?
The highest price target for ENTA is $24.00 from Roy Buchanan at JMP Securities, which represents a 220.0% increase from the current price of $7.50.
What is the lowest forecasted price for ENTA Enanta Pharmaceuticals Inc.?
The lowest price target for ENTA is $5.00 from at , which represents a -33.3% decrease from the current price of $7.50.
What is the overall ENTA consensus from analysts for Enanta Pharmaceuticals Inc.?
The overall analyst consensus for ENTA is bullish. Out of 12 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $20.00.
How accurate are ENTA stock price projections?
Stock price projections, including those for Enanta Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2025 8:54 AM UTC